Watchmaker Genomics, Inc.

SAN DIEGO, April 28, 2025 /PRNewswire/ -- CS Genetics, a leader in single cell genomics, is proud to announce the appointment of Paul McEwan as an Independent Director to its Board. Mr. McEwan brings over two decades of experience in life science tools, genomics, and strategic growth. Mr. McEwan is a serial entrepreneur in the life sciences sector, with a proven track record of founding and scaling innovative biotech companies. He co-founded Kapa Biosystems, serving as Chief Scientific Officer from 2006 until its acquisition by Roche in 2015. Under his leadership, Kapa Biosystems pioneered the use of directed evolution to develop high-performance reagents for life science applications. In addition to Kapa Biosystems, Mr. McEwan co-founded Agencourt Bioscience and Agencourt Personal Genomics. These ventures collectively achieved an exit value of over $700 million, underscoring his ability to generate significant commercial and financial returns from venture-stage life-science companies. Beyond his entrepreneurial ventures, Mr. McEwan is an active angel investor, focusing on early-stage companies in life science tools and diagnostics. He currently serves as Chairman of DNA Script and SeqWell, and as a Board Member of Watchmaker Genomics, Oligo Factory and Codetta Bio. "We are thrilled to welcome Paul to our Board of Directors," said Bill Colston, CEO of CS Genetics. "His extensive experience in genomics and strategic growth will be invaluable as we continue to advance our mission of democratizing single cell genomics." About CS Genetics CS Genetics is a privately held genomics-technology company based in San Diego, California. The company has developed a radically new, instrument-free platform for single-cell genomics with disruptive simplicity, speed, and scalability that will launch a new era of NGS-based cellular analysis. The company's technology leverages a molecular process known as Kinetic Confinement that is categorically different to other single cell technologies, and plugs seamlessly into standard, widespread lab infrastructure. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, visit . Media Contact: Matt Browning Director of Marketing CS Genetics, Inc. [email protected] SOURCE CS Genetics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BOULDER, Colo.--(BUSINESS WIRE)-- Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection. “We are pleased to bring our RNase Inhibitor to market,” said Sandra Rowe, Vice President of Marketing at Watchmaker. “We aim to be a partner for our customers and provide high-performing yet cost-effective solutions to allow for higher throughput and increased sensitivity.” Key features of Watchmaker’s RNase Inhibitor include: Robust protection against RNA degradation at elevated temperatures High-quality performance at a competitive price point The launch of the RNase Inhibitor complements Watchmaker’s Precision Enzymes portfolio, which includes the highly thermostable and inhibitor-tolerant StellarScript HT+ Reverse Transcriptase designed for sensitive pathogen detection assays. For more information, visit watchmakergenomics.com. About Watchmaker Genomics Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. For more information, please visit , follow Watchmaker Genomics on Twitter @WatchmakerGeno1 or find us on LinkedIn.

As a ComboMATCH-designated lab, Exact Sciences will use its OncoExTra test to examine tumour tissue and associated normal blood samples to identify the precise tumour abnormalities that may be most effective for treatment The OncoExTra therapy selection test from Exact Sciences. (Credit: PRNewswire/EXACT SCIENCES CORP) US-based Exact Sciences said that its testing laboratory in Phoenix, Arizona and its OncoExTra test have been selected by the National Cancer Institute (NCI) to take part in the ComboMATCH (Molecular Analysis for Combination Therapy Choice) clinical trials. ComboMATCH is a coordinated set of precision medicine cancer clinical trials to evaluate new combinations of cancer drugs guided by tumour biology. It is being led by the ECOG-ACRIN Cancer Research Group and NCI, which is part of the National Institutes of Health (NIH). OncoExTra is a next-generation sequencing (NGS) test launched in February this year. It is said to offer an overall molecular picture of the patient’s cancer and actionable results to match a patient’s cancer to a targeted therapy or trial. As a ComboMATCH-designated lab, the American cancer screening and diagnostic tests provider will use its OncoExTra therapy selection test to examine tumour tissue and associated normal blood samples. This will help identify the precise tumour abnormalities that may be most effective for treatment. The ComboMATCH registration study is expected to serve as the entry point to a series of clinical trials for assessing anti-cancer treatment combinations. This will be in a subset of adults and children with locally advanced or metastatic cancer, as determined by NGS testing. Exact Sciences precision oncology chief medical officer Rick Baehner said: “The ComboMATCH trials will use our OncoExTra test to provide the most informed picture of a patient’s individual tumour biology. “We are eager to work with trial investigators and are proud the NCI chose Exact Sciences for this important initiative. “Our company is dedicated to providing comprehensive tumour information for patients in clinical trials like ComboMATCH, and to enabling the delivery of personalised cancer care.” In a separate development, Exact Sciences signed a multi-year, co-exclusive deal with US-based Watchmaker Genomics to develop and commercialise the DNA methylation analysis technology, TET-assisted pyridine borane sequencing (TAPS). Additionally, both firms have signed a supply agreement under which Watchmaker Genomics will provide Exact Sciences access to its sequencing reagents and precision enzymes portfolio. Watchmaker Genomics CEO Trey Foskett said: “This arrangement provides us with an exciting opportunity to accelerate the development and commercialisation of a game-changing technology to the benefit of the broader research and clinical genomics markets.”